Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. Issue 11 (8th November 2017)

• Record Type: Journal Article
• Authors: Gulati, Geeta; Heck, Siri L.; Røsjø, Helge; Ree, Anne H.; Hoffmann, Pavel; Hagve, Tor‐Arne; Norseth, Jon; Gravdehaug, Berit; Steine, Kjetil; Geisler, Jürgen; Omland, Torbjørn
• Is Part Of: Journal of the American Heart Association. Volume 6:Issue 11(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-11-08
• Subjects: beta‐blocker -- brain natriuretic peptide -- cardio‐oncology -- C‐reactive protein -- magnetic resonance imaging -- troponin; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.117.006513
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Anthracyclines are associated with cardiotoxic effects. Cardiovascular biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may precede and predict the development of left ventricular impairment. The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on‐treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines. Methods and Results: This report encompasses 121 women included in the 2×2 factorial, placebo‐controlled, double‐blind PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) trial with metoprolol and candesartan given concomitantly with anticancer therapy containing the anthracycline, epirubicin (total cumulative dose, 240–400 mg/m 2 ). Cardiovascular magnetic resonance, echocardiography images, and circulating levels of biomarkers were obtained before and after anthracycline treatment. Cardiac troponins I and T, B‐type natriuretic peptide, N‐terminal pro‐B‐type natriuretic peptide, C‐reactive protein, and galectin‐3 increased during anthracycline therapy (all P <0.05). The troponin response was attenuated by metoprolol ( P <0.05), but not candesartan. There was no association between change in biomarker concentrations and change in cardiac function during anthracycline therapy. Conclusions: Treatment with contemporary anthracycline doses for early breast cancer is associated with increase in circulating cardiovascular biomarkers. This increase is, however, not associated with early decline in ventricular function. Beta‐blockade may attenuate early myocardial injury, but whether this attenuation translates into reduced risk of developing ventricular dysfunction in the long term remains unclear. Clinical Trial Registration: URL:http://www.clinicaltrial.gov . Unique identifier: NCT01434134.